CERENOME, INC. 10-Q

Item 1A. Risk Factors For a discussion of certain factors that could materially affect our business, financial condition, and operating results or that could cause actual results to differ materially from the results described in or implied by the forward-looking statements in this Quarterly Report on Form 10-Q, in addition to the information in the section entitled “Cautionary Statement Regarding Forward-Looking Statements,” you should carefully review and consider the information under “Part I, Item 1A- Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021. There have been no material changes to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2021. 23 Item 6. Exhibits EXHIBIT INDEX PLUS THERAPEUTICS, INC. Exhibit Number Exhibit Title Filed with this Form 10-Q Incorporated by Reference Form File No. Date Filed 1.1 Distribution Agreement, dated January 14, 2022, by and among Plus Therapeutics, Inc. and Canaccord Genuity LLC 8-K 001-34375 Exhibit 1.1 01/14/2022 3.1 Composite Certificate of Incorporation 10-K 001-34375 Exhibit 3.1 03/11/2016 3.2 Certificate of Amendment to Amended and Restated Certificate 8-K 001-34375 Exhibit 3.1 05/10/2016 3.3 Certificate of Amendment to Amended and Restated Certificate 8-K 001-34375 Exhibit 3.1 05/23/2018 3.4 Certificate of Amendment to Amended and Restated Certificate 8-K 001-34375 Exhibit 3.1 07/29/2019 3.5 Certificate of Amendment to Amended and Restated Certificate 8-K 001-34375 Exhibit 3.1 08/06/2019 3.6 Amended and Restated Bylaws of Plus Therapeutics, Inc. 8-K 001-34375 Exhibit 3.1 09/21/2021 10.1+ Medidata Services Agreement and Statement of Work X 10.2 Distribution Agreement, dated January 14, 2022, by and among Plus Therapeutics, Inc. and Canaccord Genuity LLC. 8-K 011-34375 Exhibit 1.1 1/14/2022 31.1 Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 X 31.2 Certification of Principal Financial and Accounting Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 X 32.1* Certifications Pursuant to 18 U.S.C. Section 1350/ Securities Exchange Act Rule 13a-14(b), as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002 X 101.INS Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document X 101.SCH Inline XBRL Schema Document X 101.CAL Inline XBRL Calculation Linkbase Document X 101.DEF Inline XBRL Definition Linkbase Document X 101.LAB Inline XBRL Label Linkbase Document X 24 101.PRE Inline XBRL Presentation Linkbase Document X . 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) X + Portions of this exhibit have been excluded in compliance with Item 601 of Regulation S-K. * In accordance with Item 601(b)(32)(ii) of Regulation S‑K and SEC Release No. 34‑47986, the certifications furnished in Exhibit 32.1 hereto is deemed to accompany this Form 10‑Q and will not be deemed “filed” for purposes of Section 18 of the Exchange Act or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933 except to the extent that the Company specifically incorporates it by reference. 25 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. PLUS THERAPEUTICS, INC. By: /s/ Marc H. Hedrick Dated: April 21, 2022 Marc H. Hedrick President & Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer) By: /s/ Andrew Sims Dated: April 21, 2022 Andrew Sims Chief Financial Officer (Duly Authorized Officer and Principal Financial Officer and Principal Accounting Officer) 26